Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07520292 · ClinicalTrials.gov registry record · Phase 1
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder
A Phase 1 study, sponsored by Newleos Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT07520292 is a Phase 1 study that is actively recruiting participants, run by Newleos Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT07520292, a Phase 1 study, is actively recruiting participants, sponsored by Newleos Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary goal of this Phase 1b clinical trial is to evaluate the effects of a novel TAAR1 receptor partial agonist (NTX-2001) in adults with Alcohol Use Disorder (AUD). The main questions this trial aims to answer are: * Does NTX-2001 affect alcohol consumption in adults with AUD? * Is NTX-2001 safe and well tolerated in adults with AUD? Researchers will compare the effects of NTX-2001 with matching placebo (look-alike capsule that contains no drug). Participants will: * Take NTX-2001 or matching placebo every day for 2 weeks * Visit the clinic 4 times over the course of 10 weeks
Interventions
- DRUG Placebo
- DRUG NTX-2001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07520292
The ClinicalTrials.gov registry entry for NCT07520292 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Newleos Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07520292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07520292 about?
NCT07520292 is a clinical study titled "Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder". The primary goal of this Phase 1b clinical trial is to evaluate the effects of a novel TAAR1 receptor partial agonist (NTX-2001) in adults with Alcohol Use Disorder (AUD). The main questions this trial aims to answer are: * Does NTX-2001 affect alcohol consumption in adults with AUD? * Is NTX-2001 ...
What is the current status of trial NCT07520292?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-03-20. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07520292?
The interventions under investigation include: Placebo (DRUG), NTX-2001 (DRUG).
Who is sponsoring clinical trial NCT07520292?
This trial is sponsored by Newleos Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.